Details

Autor(en) / Beteiligte

• DeFilipp, Z
• Duarte, R F
• Snowden, J A
• Majhail, N S
• Greenfield, D M
• Miranda, J L
• Arat, M
• Baker, K S
• Burns, L J
• Duncan, C N
• Gilleece, M
• Hale, G A
• Hamadani, M
• Hamilton, B K
• Hogan, W J
• Hsu, J W
• Inamoto, Y
• Kamble, R T
• Lupo-Stanghellini, M T
• Malone, A K
• McCarthy, P
• Mohty, M
• Norkin, M
• Paplham, P
• Ramanathan, M
• Richart, J M
• Salooja, N
• Schouten, H C
• Schoemans, H
• Seber, A
• Steinberg, A
• Wirk, B M
• Wood, W A
• Battiwalla, M
• Flowers, M E D
• Savani, B N
• Shaw, B E

Titel

Metabolic syndrome and cardiovascular disease following hematopoietic cell transplantation: screening and preventive practice recommendations from CIBMTR and EBMT

Ist Teil von

• Bone marrow transplantation (Basingstoke), 2017-02, Vol.52 (2), p.173-182

Ort / Verlag

England: Nature Publishing Group

Erscheinungsjahr

2017

Link zum Volltext

Quelle

Free E-Journal (出版社公開部分のみ）

Beschreibungen/Notizen

• Metabolic syndrome (MetS) is a constellation of cardiovascular risk factors that increases the risk of cardiovascular disease, diabetes mellitus and all cause mortality. Long-term survivors of hematopoietic cell transplantation (HCT) have a substantial risk of developing MetS and cardiovascular disease, with the estimated prevalence of MetS being 31-49% among HCT recipients. Although MetS has not yet been proven to impact cardiovascular risk after HCT, an understanding of the incidence and risk factors for MetS in HCT recipients can provide the foundation to evaluate screening guidelines and develop interventions that may mitigate cardiovascular-related mortality. A working group was established through the Center for International Blood and Marrow Transplant Research and the European Group for Blood and Marrow Transplantation with the goal of reviewing literature and recommend practices appropriate to HCT recipients. Here we deliver consensus recommendations to help clinicians provide screening and preventive care for MetS and cardiovascular disease among HCT recipients. All HCT survivors should be advised of the risks of MetS and encouraged to undergo recommended screening based on their predisposition and ongoing risk factors.